Partnering
Our modular approach to ADC design enables partnering flexibility, with strategic collaborations tailored to deliver maximum value for patients and partners.
With over 20 years of ADC expertise, we offer a differentiated platform portfolio including a best-in-class universal masking technology, in addition to first-in-class antifolate and immunostimulatory phosphonate payloads. Our innovative platforms work independently or in combination to address multiple hallmarks of cancer, providing partners with powerful tools to tackle difficult-to-treat tumors.
Our end-to-end capabilities, spanning pre-clinical and clinical R&D, GMP manufacturing, and regulatory engagement, enable efficient development from discovery through to commercial launch. We are open to exploring strategic collaborations, licensing opportunities, and co-development partnerships across our platforms and proprietary programs.
EU and FDA Inspected & Approved Manufacturing Facilities
Byondis has in-house Good Manufacturing Practice (GMP) manufacturing and conjugation facilities for both mAbs and ADCs, right up to early commercial launch scale.
Our team of approximately 200 highly qualified employees work in our state-of-the art research and development and GMP production facilities in Nijmegen, the Netherlands. Our activities span across 73,000 square meters, combining leading expertise in precision oncology drug development with proven GMP delivery capabilities.
Contact us by filling in the form below or send an email to BD@Byondis.com
Personal data contained in this form is intended for the sole use of Byondis.
We will use this data to respond to your question or obtain additional information from you as needed.
Please see the Byondis Privacy and cookie statement.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical development, process development and manufacturing.
Investors & Media
Byondis is an independent clinical stage fully integrated biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) with a focus on antibody-drug conjugates and antibody-based therapeutics.
Our Science
Our novel drug development platform is based on multiple, seamlessly integrated, proprietary technologies with enhanced tumor targeting selectivity, optimized linkers, broad diversity of targets, payloads & MoA.
Who We Are
At Byondis, we are dedicated to transforming the lives of those affected by cancer.
